Fig. 1

Analysis of variations in HSP90B1 expression and its prognostic significance across various cancer types in pan-cancer. A Differential expression of HSP90B1 between cancer and peritumoral tissue in multiple samples obtained from the TCGA database. Symbols “*”, “**”, and “***” denote statistical significance with p < 0.05, p < 0.01, and p < 0.001, respectively (Student t-test). B Differential expression of HSP90B1 between cancer tissue obtained from samples in the TCGA database and peritumoral tissue obtained from samples in the TCGA and GTEx database. Symbols “*”, “**”, and “***” denote statistical significance with p < 0.05, p < 0.01, and p < 0.001, respectively (Student t-test). C, D Protein expression profiling of HSP90B1 in lung cancer and adjacent normal lung tissue, as well as in colon cancer and normal colon tissue. E–G Forest plot of single Cox regression analysis depicting HRs of HSP90B1 in pan-cancer for OS, PFI and DSS. Only p < 0.05 signifies a significant association between HSP90B1 expression and cancer prognosis. HR > 1 suggests that elevated HSP90B1 expression is indicative of a heightened risk for poor prognosis. (H-M) Box plots depicting correlation between HSP90B1 expression and tumor staging in BLCA, KIRC, KIRP, OV, THCA and TGCT. The central box encapsulates the interquartile range (IQR) of HSP90B1 expression, featuring the median as a line within the box. The whiskers extend to values within 1.5 times the IQR, representing the range of maximum and minimum expression. Symbols “*”, “**”, and “***” denote statistical significance with p < 0.05, p < 0.01, and p < 0.001, respectively (Student t-test). (N–O) Heat maps demonstrating correlation between HSP90B1 expression and immune infiltrating cells, immune checkpoint genes in Pan-Cancer. Symbols “*”, “**”, and “***” denote statistical significance with p < 0.05, p < 0.01, and p < 0.001, respectively (Pearson correlation).(P-Q) Effect of HSP90B1 inhibitor PU-WS13 on proliferation of leukemia cells (MV4-11, 48 h treatment, n = 3) and solid tumor cells (lung cancer H1299, 48 h treatment, n = 3).Symbols “*” and “**”denote statistical significance with p < 0.05 and p < 0.01 respectively (Student t-test).(R-S) Effect of HSP90B1 inhibitor PU-WS13 on the immune checkpoint PD-L1 cell surface expression level in leukemic cells (MV4-11, 75 μM 48 h treatment) and solid tumor cells (lung cancer H1299, 50 μM 48 h treatment). Symbol “**” denotes statistical significance with p < 0.01 (Student t-test)